Collaborative Seamless Care in Oncology : Measure and Reinforce Safety and Adherence to Oral Cancer Treatment

This study is currently recruiting participants.
Verified July 2012 by Policlinique Médicale Universitaire
Sponsor:
Collaborator:
Centre Hospitalier Universitaire Vaudois
Information provided by (Responsible Party):
Marie Schneider, Policlinique Médicale Universitaire
ClinicalTrials.gov Identifier:
NCT01370980
First received: June 3, 2011
Last updated: July 16, 2012
Last verified: July 2012

June 3, 2011
July 16, 2012
July 2010
December 2011   (final data collection date for primary outcome measure)
Change in Medication adherence [ Time Frame: 3 months, 6 months, 9 months, 12 months ] [ Designated as safety issue: No ]
MEMS data, completed by informations given in motivational interviewing
Same as current
Complete list of historical versions of study NCT01370980 on ClinicalTrials.gov Archive Site
  • Program implementation [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    Evaluating the implementation of the program in pharmacies
  • Oncologists, nurses, pharmacists and patients satisfaction [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    By questionnaire and interviews
  • Effect of Adverse Drug Reaction (ADR) on medication adherence [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
    By MEMS data and motivational interviewing informations
  • Change in Adverse Drug Reaction (ADR) [ Time Frame: 3 months, 6 months, 9 months, 12 months ] [ Designated as safety issue: Yes ]
    To evaluate the frequency and severity of ADR and the pharmacist's contribution to their management. Data from motivational interviewing.
  • Program implementation [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    Evaluating the implementation of the program in pharmacies
  • Oncologists, nurses, pharmacisits and patients satisfaction [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    By questionnaire and interviews
  • Effect of Adverse Drug Reaction (ADR) on medication adherence [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
    By MEMS data and motivational interviewing informations
  • Change in Adverse Drug Reaction (ADR) [ Time Frame: 3 months, 6 months, 9 months, 12 months ] [ Designated as safety issue: Yes ]
    To evaluate the frequency and severity of ADR and the pharmacist's contribution to their management. Data from motivational interviewing.
Not Provided
Not Provided
 
Collaborative Seamless Care in Oncology : Measure and Reinforce Safety and Adherence to Oral Cancer Treatment
Collaborative and Seamless Care in Oncology : a Study in Primary Care to Measure and Reinforce Safety and Adherence to Oral Cancer Treatment

The purpose of this study is to implement a support interdisciplinary program(oncologists, pharmacists, physicians, nurses, leagues against cancer) of medication adherence to oral oncology treatments. The aim is to ensure continuity of care between professionals,effectiveness of treatment and patient safety.

80 patients will be included in swiss-romande hospitals and private oncologists and followed by thirty study pharmacies. Each refusal and drop-out will be documented. Follow-up duration is 48 weeks, with a motivational interviewing at least every three months. Patient adherence will be assessed electronically by MEMS (Medication Event Monitoring System).

Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Patient with cancer treated by oral medication in swiss-romande hospitals and private oncologists, and enrolled in the adherence program in one of the thirty studies pharmacies.

Cancer
Not Provided
Study population
Adults (18 years old or more) with one of the following oral oncology treatments: letrozole, exémestane, imatinib, sunitinib, nilotinib, evérolimus, déférasirox
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
80
September 2014
December 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • 18 years and older
  • Treated for a cancer with oral medication (letrozol, exemestan,imatinib, sunitinib, nilotinib, everolimus, deferasirox)
  • French speaking

Exclusion Criteria:

- None

Both
18 Years and older
No
Not Provided
Switzerland
 
NCT01370980
139/10
No
Marie Schneider, Policlinique Médicale Universitaire
Policlinique Médicale Universitaire
Centre Hospitalier Universitaire Vaudois
Study Chair: Bugnon Olivier, Professor Policlinique Médicale Universitaire
Study Chair: Lüthi François, Dr Clinique Bois-Cerf, Lausanne
Principal Investigator: Schneider Marie-Paule, PhD Policlinique Medicale Universitaire
Principal Investigator: Chevaux Bernard, Dr Centre Hospitalier Universitaire Vaudois
Principal Investigator: Troxler Stéphanie, PhD Student Policlinique Medicale Universitaire
Principal Investigator: Leila Achtari, MD Centre Hospitalier Univeristaire Vaudois
Policlinique Médicale Universitaire
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP